Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Frequently asked questions
What sector does Rein Therapeutics Inc (RNTX) operate in?
Rein Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Rein Therapeutics Inc (RNTX) current stock price?
As of the latest data, Rein Therapeutics Inc stock price is $0.58, with a previous close of $0.58. Rein Therapeutics Inc gained $0.00 in the last trading session, representing a 0.19% increase.
What is Rein Therapeutics Inc (RNTX) current market capitalization?
Rein Therapeutics Inc market cap is approximately 50.31 million.
What is Rein Therapeutics Inc (RNTX) Earnings Per Share (EPS)?
The trailing EPS is -$1.68, and the forward EPS is -$0.47.
What is Rein Therapeutics Inc (RNTX) EBITDA?
Rein Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.38 million.
Does Rein Therapeutics Inc (RNTX) pay dividends?
No. Rein Therapeutics Inc does not pay a dividend.
What is Rein Therapeutics Inc (RNTX) beta (volatility) score?
Rein Therapeutics Inc has a beta of 1.373, suggesting it is more volatile than the market.
